Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
Phase 3
Recruiting
- Conditions
- Interventions
- Registration Number
- NCT05451615
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Brief Summary
The aim of this study is to observe the clinical efficacy and safety of abatacept combined with JAK inhibitor in the treatment of D2TRA patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
- Meet the above diagnostic criteria for refractory rheumatoid arthritis
- The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease-improving anti-rheumatic drugs is ineffective, and abatacept combined with a JAK inhibitor is required treated patients
Read More
Exclusion Criteria
- Patients with tumors, hematological diseases, and other autoimmune diseases
- Those who have a history of allergies to the drugs selected in this study
- Those who cannot adhere to abatacept combined with JAK inhibitor therapy, or who have serious adverse reactions and did not complete the observation period prescribed by the study
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description JAK inhibitor Janus Kinase Inhibitor D2T RA patients receive JAKi Abatacept Abatacept D2T RA patients receive Abatacept JAK inhibitor Abatacept D2T RA patients receive JAKi
- Primary Outcome Measures
Name Time Method Efficacy of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis maximum 1 years The disease activity score of 28 joints with erythrocyte sedimentation rate (DAS28-ESR ≤ 2.6, remission; 2.6 \< DAS28-ESR ≤ 3.2, mild activity; 3.2 \< DAS28-ESR ≤ 5.1, moderate activity, and DAS28-ESR \> 5.1, severe activity)
- Secondary Outcome Measures
Name Time Method Incidence of Treatment-Emergent Adverse EventsArthritis maximum 1 years Liver and kidney function
Trial Locations
- Locations (1)
Zhejiang Provincial People's Hospital
🇨🇳Hangzhou, Zhejiang, China